demcizumab   Click here for help

GtoPdb Ligand ID: 8451

Synonyms: OMP-21M18 | OMP21M18
Compound class: Antibody
Comment: Demcizumab is a humanised IgG2 monoclonal antibody targeting DLL4 (delta like canonical Notch ligand 4), a membrane bound Notch receptor ligand expressed predominantly on vascular endothelial cells.
Peptide sequence information for this antibody is available from its IMGT/mAb-DB record. A BLAST search using the peptide sequence of the variable region of the heavy chain forming demcizumab reveals US7750124 B2 as the covering patent [2].
No information available.
Summary of Clinical Use Click here for help
Demcizumab was advanced to clinical trials in patients with advanced solid tumours (max phase 2). However, development appears to have been discontinued.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Epitope mapping reveals that demcizumab binds to an epitope within the DSL domain (Delta/Serrate/lag-2) of DLL4 [2]. Demcizumab binds to DLL4 (delta like canonical Notch ligand 4) and prevents this ligand from activating receptors of the Notch signalling pathway. Notch pathway inhibition has anti-cancer effects.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02259582 A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer Phase 2 Interventional Mereo BioPharma 3
NCT00001693 Phase I-II Multiple-Dose Safety and Efficacy Study of a Selective Inhibitor of Cyclooxygenase - 2 (SC-58635) in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients and Carriers Phase 1 Interventional National Institutes of Health Clinical Center (CC) 1